Document is current
Any future updates will be listed below
-
Authors
Ben Bashat, Dafna https://orcid.org/0000-0001-8396-1031
Thaler, Avner
Lerman Shacham, Hedva
Even-Sapir, Einat
Hutchison, Matthew
Evans, Karleyton C.
Orr-Urterger, Avi
Cedarbaum, Jesse M.
Droby, Amgad https://orcid.org/0000-0002-6182-0059
Giladi, Nir
Mirelman, Anat
Artzi, Moran
-
Funding
Funding for this research was provided by:
Biogen Inc. Grant number 20416.
- License Information
-
More Information
Article History
Received: 18 April 2022
Accepted: 30 September 2022
First Online: 21 October 2022
Competing interests
: D.B.B., H.L.S., E.E.S., A.O.-U., A.D., and M.A. report no competing interests, and no competing non-financial interests. A.T. reports no competing interests relevant to this work. He received honoraria from Abbvie- Israel. M.H. and K.C.E. report no competing interests relevant to this work. Both are employees of and own stock in Biogen. J.M.C. is a former employee of Biogen. N.G. has no competing interests about this work. He serves as a member of the editorial board for the Journal of Parkinson’s Disease. He serves as a consultant to Sionara, Accelmed, Teva, NeuroDerm, Intec Pharma, Pharma2B, Denali, and Abbvie. He received royalties from Lysosomal Therapeutics (LTI) and payment for lectures at Teva, UCB, Abbvie, Sanofi-Genzyme, and Bial and Movement Disorder Society. He received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program, and the Israel Science Foundation as well as from Teva NNE program, Biogen, LTI, and Pfizer. A.M. reports no competing interests relevant to this work. She reports serving as an advisor to Neuroderm.
